Current and Emerging Themes in the Structural Analysis of Viral RNA Genomes: Applications for the Development of Novel Therapeutic Drugs by Romero-López, Cristina & Berzal-Herranz, Alfredo
GENOMICS AND COMPUTATIONAL BIOLOGY Vol. 1, No. 1 (2015): e15 
Publisher: Kernel Press. Copyright © 2015 Romero-López and Berzal-Herranz. This is an Open Access article distributed under the terms of 
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, 
and reproduction in any medium, provided the original work is properly cited.  
 
Review 
Current and Emerging Themes in the Structural Analysis of 
Viral RNA Genomes: Applications for the Development of Novel 
Therapeutic Drugs  
Cristina Romero-López
*
 and Alfredo Berzal-Herranz
*  
Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC. PTS Granada, Armilla 18016. Granada. Spain. 
*To whom correspondence should be addressed: aberzalh@ipb.csic.es; cristina_romero@ipb.csic.es 
Received 2015-02-04; Accepted 2015-04-03; Published 2015-09-18  
ABSTRACT 
RNA molecules assume different roles in many 
different biological processes. This functional diversity 
is intimately related to RNA folding. In recent years, 
advances in the field of structure analysis by high-
throughput methodologies and the development of 
novel potent bioinformatic tools have enabled the first 
structural maps of the eukaryotic transcriptome and 
the further establishment of novel function-structure 
relationships. This important progress has been of 
special relevance in the field of molecular virology. 
Viral genomes are compact entities that require 
overlapping coding levels to bear all the genetic 
information required for viral propagation. This is 
achieved by the acquisition of functional RNA 
domains, structurally conserved encoding units that 
perform essential roles for the consecution of the viral 
cycle. Interfering with the activity of these structural 
elements offers a potential means of treating viral 
infections, such as that caused by the hepatitis C 
virus, HCV. This review summarizes major 
achievements in the development of emerging 
methodologies for the analysis of RNA folding and 
their application to the study of the HCV genome 
structure. It will also examine the progress toward the 
design of novel antiviral compounds based in nucleic 
acids able to interfere with the folding of functional 
RNA domains.   
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INTRODUCTION 
Advances in next generation sequencing 
techniques have provided a wide overview of the 
genetic organization in many organisms. These 
studies have revealed that protein coding genes are 
just a reduced fraction of the total genetic information, 
which cannot explain the complexity and variety of 
biological functions. Therefore, additional functional 
elements must be encoded in the rest of the genomic 
nucleotide sequence. The knowledge that RNA 
molecules can act as regulatory and catalytic elements 
prompted numerous studies that finally placed RNA as 
a key partner of the cell survival in all the living 
organisms [1]. As for protein-mediated catalysis, RNA 
function is also dependent on its three-dimensional 
(3D) conformation, as observed from X-ray 
crystallography studies performed with catalytic RNA 
molecules [2-6]. For example, investigations showed 
that conformational rearrangements were required for 
the efficient catalysis mediated by these ribozymes [7].  
The knowledge about RNA 3D structure has 
undergone rapid explosive growth since the first 
crystallographic studies performed with the yeast 
phenylalanine transfer RNA (tRNA) [8-10]. Since then, 
RNA folding started to be considered as a dynamic 
and hierarchical system defined by primary, 
secondary, tertiary and quaternary structure, in 
contrast to proteins. Primary structure, or RNA 
sequence, is widely used for covariation analysis of 
different RNA molecules. This is the first step in the 
identification of conserved structural elements and 
allows for defining molecular RNA families. RNA 
secondary structure is defined by base-pair 
interactions conforming stems that appear joined and 
closed by different types of loop: apical loops, internal 
loops, bulges or junction loops [11]. These loops exert 
an effect on the surrounding residues or can act as 
global controllers of RNA folding by 
distorting/bending/unwinding long-distant helixes, thus 
contributing to the overall architecture of the RNA 
molecule. The tertiary structure motifs act as fixing 
partners to stabilize the 3D folding. These include 
coaxial helixes, tetraloop-tetraloop interactions, kissing 
loops contacts, pseudoknots, ribose zippers, 
dinucleotide platforms and duplexes stacking, either 
side by side or orthogonally [12]. Finally, quaternary 
structure relies on intermolecular contacts, which are 
ultimately governed by secondary and tertiary 
interactions. As well as this substantial complexity, 
RNA molecules are dynamic entities, which can adopt 
a wide range of slightly different conformations to 
promote distinct biological roles. Therefore, the main 
question now resides in deciphering the biophysical 
relationship between the structure and the biological 
function. For that purpose, biochemical, biophysical 
and mutational analyses, together with the use of 
novel bioinformatic strategies, must be combined and 
applied. These investigations will also contribute to 
expand our knowledge about key biological processes 
mediated by RNA molecules, such as transcription 
elongation, splicing or translation [1].  
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RNA plasticity acquires special relevance in RNA 
viruses. They have developed sophisticated genomes, 
which can store all the information required for their 
preservation and propagation in a minimum size. This 
is achieved by overlapping several information coding 
levels. Besides protein coding sequence, nucleotides 
also encode structural information, which is transferred 
into an intricate regulatory network governed by an all-
RNA based mechanism. The main achievement of this 
system is to use a small portion of genetic information 
to play a number of different roles. These structural 
regions, the so-called functional RNA domains, 
provide a robust genetic background [13-15], which 
overcomes the variable and complex viral pool 
dynamics. It is noteworthy that the same features that 
achieve proficient viral fitness also provide a potential 
tool for destroying them. Thus, novel nucleic acids-
based drugs targeting conserved functional genomic 
domains are now fundamental components in the 
antivirals toolbox [16].  
This review briefly summarizes those biochemical 
techniques used for the elucidation of RNA folding and 
comments their application to a practical example, the 
hepatitis C virus genome. It also reflects the 
importance of RNA structure as a critical regulatory 
element for the consecution of the viral cycle and 
provides an updated overview of the nucleic acid-
based compounds targeting genomic functional HCV 
domains. 
STUDYING RNA FOLDING 
RNA folding is a dynamic process by which 
complex architectures can be acquired by combining 
structural units, as a scaffold. RNA can adopt a 
number of different conformations, sometimes with 
roughly equal abundances, thus yielding complex 
conformational pools. These features complicate the 
study of the final folding and prompt the use of reliable 
routes for the structural analysis.  
In the initial steps of RNA structure analysis, 
comparative sequence phylogenetic studies are 
recommended to predict potential base-pairs [17-20]. 
This theoretical study informs about the conservation 
rate of RNA structural elements and is the first choice 
strategy for determining the secondary structure of a 
novel RNA. The method is based on the high 
conservation rate of structural motifs in RNA 
molecules with sequence homology. This approach 
requires large sets of highly related RNA sequences 
for yielding robust information.  
Sometimes comparative analyses are not possible, 
as in the case that no homologous sequences are 
available. In these cases, preliminary studies of the 
RNA secondary structure can be accomplished by 
theoretical in silico strategies [21]. The most employed 
softwares for predicting secondary structures from 
single molecules use the free energy minimization 
principle. In the equilibrium, a given RNA molecule 
switches from its “unfolded” state to its folded isoform. 
Both conformations exhibit a free energy value (Gibbs 
energy). The change in the Gibbs energy value 
between them quantifies the likeliness of acquiring 
such folding. Estimating free energy change values 
can be made by applying the nearest neighbor model. 
It focuses on independent base-pairs and their 
relationships with close nucleotides. Thus, the change 
in the total free energy for the structure under study 
can be calculated by adding up the single energies of 
each base-pair plus those computed for the individual 
nucleotides composing the loops. This is assessed by 
applying a dynamic programming algorithm. The main 
drawback of this theoretical strategy is the assumption 
that the RNA has a single conformation and that the 
architecture of every nucleotide will not be affected by 
distant residues. These proposals may not be true for 
all the RNA sequences. In such cases, the calculation 
of the free energy minimization is supplemented with 
partition functions that reflect the probability of each 
base pair. This calculation will reflect the accuracy of 
the prediction and, therefore, it is recommended to be 
used for all the RNA molecules tested. It is available 
from the Vienna [22] and RNAstructure [23] packages. 
Theoretical in silico studies must be further 
confirmed by experimental techniques. Though high-
resolution structural methods, such as nuclear 
magnetic resonance (NMR) and X-ray crystallography 
are key supports for structural biology knowledge and 
must be the ultimate goal in structural research, they 
present a number of drawbacks. They are laborious 
and limited in their applicability since they require short 
RNA molecules with highly compact folding, and 
therefore they are not useful for determining dynamic 
architectures in long RNA constructs. Even more, to 
know about the exact architecture of each atom is not 
always required for understanding RNA function. 
Therefore, in most cases, other commonly affordable 
biochemical and biophysical techniques provide major 
information to gain insights into the folding mechanism 
and are invaluable for interpreting high-resolution 
structure results. In this context, the use of chemical 
and/or enzymatic reagents that specifically modify or 
cleave nucleotides in a structure-dependent way is a 
common approach to elucidate the secondary and 
tertiary structure of an RNA molecule. The affected 
residues are scored as reverse transcription stops and 
resolved by high-resolution gel or capillary 
electrophoresis [24] (Figure 1A). Reactions are 
compared to a non-treated experiment and to a 
dideoxy- sequencing ladder for the identification of 
each nucleotide position [25, 26].  
Many different chemical reagents can be used to 
examine different facets of both secondary and tertiary 
structure of a given RNA molecule. For example, the 
solvent accessibility of the RNA backbone can be 
analyzed by hydroxyl radical footprinting. This is a 
straightforward and reliable method to detect high-
order, closely packed regions within an RNA molecule 
to give insights into its global architecture [27]. Further, 
backbone flexibility can be monitored by selective 2’-
hydroxyl acylation analyzed by primer extension 
methodology (SHAPE) [28-30]. SHAPE has been 
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Figure 1. RNA structure mapping. A) RNA folding analysis by chemical probing or SHAPE technology. The RNA is treated 
with chemical probes that covalently modify nucleotides at specific positions in a structure-dependent manner. Untreated 
samples must be also included in the assay for background normalization. These modifications, depicted by blue dots, act as 
stop signals in a reverse transcription (RT) reaction. Fluorescently labeled color-coded primers are used to further map each 
modified residue. The resulting cDNA products are resolved by automated capillary electrophoresis. Raw data are scaled and 
normalized to render the relative reactivity values at each nucleotide. B) Overview of the basic SHAPE-Seq experiment. RNA 
molecules are treated with SHAPE reagents or any other probe able to covalently modify the RNA in a structure-dependent way. 
Control reactions are performed in the absence of chemical probe. Adducts are detected as stop signals during the RT reaction, 
thus yielding a pool of cDNA molecules of variable length, which reflects the frequency of each modified position. Adapters 
required for further sequencing in Illumina equipment are ligated to the 3’ end of the cDNA. This ssDNA pool is further subjected 
to partial amplification with specific primers that include the corresponding code bars and adapter sequences. Sequencing reads 
are aligned and corrected to calculate the relative frequency of each modified nucleotide to generate the reactivity profile. C) 
Schematic representation of a general SHAPE-MaP assay. In this case, under specific reaction conditions, chemical adducts 
induce the miss-incorporation of residues, creating mutations with respect to the original sequence. The resulting cDNAs are 
then prepared for massive parallel sequencing. Hence, relative reactivity at each nucleotide position can be recorded as 
absolute mutation frequencies, and then corrected and normalized with respect to a non-treated sample to yield the reactivity 
pattern. D) Antisense oligonucleotide microarray assays. Under native folding conditions, the input RNA is internally labeled and 
hybridized with a customized panel of antisense, overlapping DNA oligonucleotides. Differential hybridization ability for each 
oligonucleotide is directly related to different solvent exposure at the target region. Fluorescent signal is quantified and 
normalized to render the relative accessibility pattern. 
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largely used during last years to model the secondary 
structure of numerous RNA molecules [25], to detect 
conformational rearrangements [26, 31-33] and to 
study interactions with proteins [34] and small ligands 
[35, 36]. This methodology can be complemented by 
the use of additional chemical probes, like dimethyl 
sulfate (DMS), which targets unpaired A, G and C 
residues; kethoxal, which modifies single-stranded 
guanine nucleotides; or 1-cyclohexyl-3-(2-(4-
morpholinyl)ethyl) carbodiimide tosylate (CMCT), able 
to detect unpaired U nucleotides and G residues to a 
less extent [37].  
Interestingly, nucleotides involved in tertiary 
interactions usually adopt stacking geometries or lie at 
turns in the backbone. These conformations, though 
relatively “rare”, are critical for the establishment of 
tertiary interactions and required for the RNA molecule 
to perform its function. The detection of such regions 
cannot be fully and successfully accomplished by the 
conventional chemical or SHAPE probes. To 
overcome this, it has been reported the use of a novel 
methodology based on SHAPE chemistry, the so-
called differential SHAPE (Dif-SHAPE) [38]. This 
strategy makes use of two different SHAPE reagents, 
N-methylisatoic anhydride (NMIA) and 1-methyl-6-
nitroisatoic anhydride (1M6) to map flexible residues 
with slow conformational dynamics as well as 
nucleotides involved in π-π stacking interactions. In 
sum, it is very advantageous for the detection of 
ligands interaction pockets and to identify pre-folded 
tertiary contacts, thus giving an idea of the overall 
geometry of a target RNA. 
An additional very useful strategy for interrogating 
about the nucleotides involved in the acquisition of 
secondary and/or tertiary structures is the molecular 
interference. In this methodology, the RNA is 
chemically modified and further partitioned to separate 
native/functional molecules from non-functional 
molecular species [39, 40]. This technique is largely 
selective for characterizing essential nucleotides 
groups and for establishing hierarchical relationships 
between residues required for the acquisition of the 3D 
folding. It is also a versatile tool since it allows for 
using different chemical reagents with different 
specificities [41]. 
Whatever the chemical probe used, relative 
reactivity quantification at each nucleotide position is 
required for inferring the secondary and tertiary RNA 
structure. Currently, the gold standard to accurately 
quantify modified nucleotides involves the use of 
capillary electrophoresis and further processing of the 
electrophoregram signals. This laborious task can be 
accomplished by different softwares, such as CAFA 
[42], FAST [43], SHAPE-CE [44], HiTRACE [45] or the 
most widely used QuShape package [46]. Particularly, 
QuShape software is a user-friendly platform that 
allows for relative automation of data processing for 
accurate, objective and reliable quantification of 
probing signals, and is currently considered one of the 
most useful bioinformatic tools for the analysis of RNA 
structural mapping. 
During recent years, the emergence of novel high-
throughput technologies that analyze sequence 
diversity and abundance of specific RNA molecules 
has prompted the development of improved methods 
for studying and understanding RNA structure at 
transcriptome scale. The combination of chemical 
probing with next-generation sequencing provides 
conformational data at nucleotide-resolution in 
complex mixtures of RNA molecules. The SHAPE-Seq 
strategy [44, 47, 48] was the first glimpse at aiming 
that goal. It ensures complete relative-reactivity 
spectrums at nucleotide-resolution level for hundreds 
of RNA molecules present in a complex mixture. 
Modified residues are detected as stops during the 
reverse transcription reaction, yielding a pool of 
cDNAs whose length distribution resembles the 
frequency of modification throughout the molecule 
(Figure 1B). One of the main drawbacks of SHAPE-
Seq is that it quantifies the frequency of RT stops, and 
thus it is biased by the efficiency of the RNA-adaptor 
ligation and specific library preparation for deep 
sequencing. These limits can be overcome by the use 
of the recently developed SHAPE-MaP (SHAPE and 
mutational profiling) technology (Figure 1C), in which 
2’O-adducts at conformationally flexible residues can 
be misread by the reverse transcriptase under certain 
simple reaction conditions [49]. SHAPE reactivity is 
recorded as mutations in the resulting cDNA and 
double-stranded DNA libraries can be generated by 
commercially available kits. Finally, an estimation of 
the mutation frequency at each residue offers a 
standard SHAPE reactivity profile that can be used to 
model secondary and tertiary structure for single mole-
cule. This methodology has been further modified and 
implemented for detecting RNA interaction groups by 
mutational profiling (RING-MaP) [50]. RING-MaP 
enables the identification of long-distance interactions 
and provides a conformational map of different 3D 
ensembles for a single RNA molecule.  
Probing structural findings are usually reinforced 
by mutational analysis and biophysical methods, such 
as small-angle X-ray scattering or FRET (fluorescence 
resonance energy transfer). This analysis offers 
additional clues about the folding and can be used to 
explore different long-distance interactions or the 
presence of suboptimal structure pools.  
Ultimately, experimental constraints derived from 
biochemical and biophysical studies can be used to 
model RNA secondary structure. For example, the 
RNAstructure package [23] 
(http://RNA.urmc.rochester.edu/RNAstructure.html) 
integrates several modules for predicting pseudoknots 
[51], consensus structures for a set of related 
sequences [52] or inferring the binding ability of 
oligonucleotides to different target RNA regions [53, 
54].  
For further prediction of tertiary nucleotide motifs, 
the MC-Fold and MC-Sym pipeline [55] was de-
signed. This strategy considers the energetic 
contribution of every residue interaction by defining 
sets of nucleotide cyclic motifs. The pipeline 
exhaustively explores the structural space of an RNA 
molecule and includes modifications to accommodate 
relative reactivity values derived from different 
chemical probing methods. This routine enables the 
prediction of secondary structures with the MC-Fold 
tool and subsequent three-dimensional modeling with 
MC-Sym.  
Alternatively, the conformational richness shown 
by RNA molecules can be also a good target for 
molecular dynamics simulations. During 80’s, initial 
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efforts for translating this methodology from proteins to 
nucleic acids were unsatisfactory and prompted the 
development of new refined algorithms. These new 
algorithms enable the incorporation of experimental 
constraints derived from probing assays with different 
chemical reagents, thus yielding accurate structural 
models [41, 50].  
Finally, evaluating the biochemical ability of RNA 
target regions to interact with other nucleic acids by 
sequence complementarity is of great interest for 
developing specific antisense oligonucleotides or 
siRNAs directed against long RNA molecules, which 
are difficult to model in silico. The antisense oli-
gonucleotides microarray technology has been 
designed to inform about the accessibility of 
consecutive tracts of nucleotides, giving data about 
the 3D architecture of the target molecule [56-58]. It 
relies in the correlation between the native folding of a 
target RNA and its ability to interact with different 
complementary DNA oligonucleotides (Figure 1D). 
DNA microarrays have been successfully used for the 
analysis of RNA fragments derived from the human 
immunodeficiency virus (HIV) [59], the hepatitis C 
virus (HCV) [26, 33, 56] or the foot-and-mouth disease 
virus (FMDV) [60, 61]. 
Together, the combination of biochemical and 
computational techniques provides complementary 
and not overlapping structural data of a RNA 
molecule. Next sections will describe their application 
to the study of the complex interaction network in the 
genomic RNA of HCV and its potential as antiviral 
target. 
FUNCTIONALLY ACTIVE STRUCTURAL RNA 
DOMAINS IN THE HCV GENOME  
Hepatitis C virus (HCV) infection is a major global 
health problem, with more than 3% of the world 
population affected (WHO data). Patients usually 
develop fibrosis, cirrhosis and even hepatocellular 
carcinoma. Current therapies based on the 
combination of pegylated-interferon (PEG-IFN-α) and 
Ribavirin are effective in only 40% of patients. Two 
recently approved direct-acting antivirals (DAAs) 
against the viral protease NS3, Boceprevir and 
Telaprevir, have improved the viral sustained 
response of a considerable number of patients given 
in cocktails with PEG-IFN-α and ribavirin. However, 
even under these high pressure conditions, the virus is 
able to escape by the generation of drug-resistant 
variants [62, 63]. Thus, the identification of new targets 
and the search for fully effective antiviral compounds 
is a major goal in HCV research. 
HCV is an enveloped RNA virus belonging to the 
Hepaciviruses spp. in the family Flaviviridae, which 
includes yellow fever virus, bovine diarrhea virus or 
Dengue virus, among others. Its genome is a positive, 
ssRNA molecule encoding a single open reading 
frame (ORF) flanked by highly conserved untranslated 
regions (UTR) [64-66] (Figure 2). The HCV genome is 
a multifunctional partner that operates, not only as 
mRNA, but it also actively governs and regulates 
different steps of the viral cycle in cis. This is achieved 
by the use of conserved functional RNA domains 
mainly located at both the 5’ and the 3’ ends of the 
viral genome. 
In the early infection, viral protein synthesis 
initiates by directly recruiting the 40S ribosomal 
subunit. This binding is directed by a highly structured 
element, which operates as internal ribosome entry 
site (IRES). Therefore, HCV translation initiation 
mechanism greatly differs to the canonical cap-
dependent mechanism, which is used by most cellular 
mRNAs for protein synthesis [67, 68]. The HCV IRES 
occurs at the 5’UTR and also spans a short stretch of 
the core coding sequence (Figure 2) [69-75]. This 
element compiles all the information that is required 
for efficient translation initiation encoded in functionally 
active RNA domains [76]. The use of such a strategy 
minimizes the requirements of host protein factors [77-
80]. In addition, structural elements of the 3’ end of the 
viral genome and in the core coding region may also 
contribute to regulate the IRES function and the 
subsequent translation elongation step [81-87].  
The architecture of the HCV IRES has been 
extensively studied by different methodologies, 
including comparative sequence analysis, 
thermodynamic-based predictions [88], enzymatic and 
chemical probing techniques, SHAPE, EMSA 
(electrophoretic mobility shift assays), NMR, X-ray 
crystallography (for a review, see [89]) and, more 
recently, atomic force microscopy (AFM) [90]. These 
analyses have offered a dynamic view of the IRES 
folding. Under physiological magnesium conditions, 
the HCV IRES region appears as an extended 
element with two major domains (II and III), which are 
organized in a single axis around a complex and 
tightly compact double-pseudoknot element (PK1 and 
PK2; Figure 2) [90-92], plus a short stem-loop 
containing the translation start codon (domain IV) [93]. 
The essential domain III contains structural elements 
that are required for efficient ribosomal recruitment 
(Figure 2). It consists of six hairpins (designated from 
IIIa-IIIf) organized around three- and four-way 
junctions, which constitute the recruitment platforms 
for eIF3 (junction IIIabc) [94] and the 40S ribosomal 
subunit (junction IIIdef) [95], with the core 40S binding 
center placed in the essential subdomain IIId [78, 96-
98]. This subdomain folds into a G-rich stem-loop with 
a rigid, asymmetric internal E-loop that resembles the 
sarcin-ricin loop of the 23S rRNA (Figure 2) [26, 43, 
99-101]. The phylogenetically conserved GGG triplet 
in the apical loop adopts a particular U-turn 
conformation that provides key properties as protein 
and nucleic acid recruitment center [96, 100].  
Accumulation of viral proteins determines the 
migration of the genomic RNA to the replication 
complex platforms. HCV RNA synthesis initiates at the 
3’UTR and is also regulated by a number of 
phylogenetically conserved functional RNA elements 
(Figure 2) [102-112].  
The 3’UTR encompasses three autonomously 
folded elements (Figure 2): i) the highly variable 
region, HV; ii) a poly U/UC-rich tract, of variable length 
and composition; iii) the essential 3’X-tail region. The 
3’X-tail is predicted to fold into two theoretical and 
mutually exclusive conformations with comparable 
thermodynamic stability (Figure 2) [113]. Both 
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Figure 2. Functional domains in the HCV genome. Figure shows the sequence and secondary structure proposed for the 5’ 
and the 3’ ends of the HCV genomic RNA, and the long-range RNA-RNA interactions established between distant regions. At 
the 5’ terminus, the minimum region for IRES activity is depicted. The entire 3’ end contains the 3’UTR plus the stem-loops 
5BSL3.1-5BSL3.3 and the Alt sequence motif at the NS5B coding sequence. The 3’X-tail folds into two alternative conformers 
with distinct functional roles. Dimer linkage sequence (DLS) is shown in grey. Pseudoknot elements are indicated as PK1 and 
PK2. The translations start and stop codons are shown in bold and marked by arrows. Nucleotide numbering corresponds to 
HCV Con1 isolate (GenBank accession number AJ238799). 
architectures preserve the 3’SLI, placed at the very 3’ 
end of the viral genome, while the 55 nts-long 
upstream region appears as a structurally dynamic 
element. This element switches from the two stem-
loops conformer (3’SLIII and 3’SLII) (Figure 2), to a 
single stem-loop exposing a palindromic nucleotide 
sequence — the so-called dimer linkage sequence, 
(DLS) — in the apical-loop [114] (Figure 2). The DLS 
initiates the HCV genome dimerization [113-115] by 
establishing a canonical apical-loop:apical-loop kissing 
interaction involving two genomic RNA molecules. 
Then, the interaction can progress toward a more 
stable extended duplex in the presence of the viral 
core chaperone protein in vitro [113-115].  
Translation and replication steps, as well as dimer 
formation, can be further regulated by conserved 
stem-loop structures placed at the 3’ end of the coding 
sequence [26, 87, 116-120] (Figure 2), which delimit 
the so-called CRE region (cis-acting replication 
element; Figure 2).The CRE is composed by three 
stem-loops: 5BSL3.1, 5BSL3.2 and 5BSL3.3 [116-
119], The 5BSL3.2 domain (also named SL9266) 
consists of two GC rich helices connected by an eight-
base bulge, and capped by a 12-base apical loop 
(Figure 2). This 5BSL3.2 has been reported to be 
critical for efficient HCV replication [118, 121] and also 
regulates viral protein synthesis [87]. These actions 
are mediated by the establishment of long-distance 
RNA-RNA interactions with other genomic RNA 
domains (see below) (Figure 2). In addition, the 
5BSL3.2 domain interacts with viral and host protein 
factors [122, 123] and constitutes a core partner in the 
regulation of the viral cycle. In contrast, the role of the 
5BSL3.1 and 3.3 domains is still unclear [121]. 
THE RNA-RNA INTERACTION NETWORK 
TUNES THE FOLDING OF ESSENTIAL 
FUNCTIONAL RNA DOMAINS IN THE HCV 
GENOME 
The progression of the HCV cycle must be finely 
regulated to achieve the viral adaptive fitness. 
Transitions between different steps of the viral cycle 
must occur at precise time points and in the proper 
molecular environment. To achieve this level of 
regulation, dynamic regulatory agents included in the 
compact structure of the viral genome are encoded.  
The 5BSL3.2 stem-loop is the perfect archetype of 
a multi-functional partner. It recruits essential protein 
factors for the HCV propagation, such as the viral 
RNA-dependent RNA polymerase or other host 
proteins [122, 123]. Further, it is the core nucleation 
center of a complex long-distance RNA-RNA in-
teraction network that operates in the HCV RNA 
genome (Figure 2). By swapping among different 
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contacts with essential structural domains of the viral 
RNA, 5BSL3.2 promotes conformational 
rearrangements, not only in the directly involved 
residues and surrounding areas, but also, in an 
indirect manner, in the rest of partners that compose 
the network [33]. These changes in the global 
architecture of the genomic RNA would finally promote 
the switch between different stages of the viral cycle. 
To accomplish this, the 5BSL3.2 domain makes use of 
its apical loop and the internal bulge (Figure 2): 
i) The apical loop is complementary to the apical 
loop of the 3’SLII within the 3’X-tail [118, 124-126], 
folded in the non-dimerizable form. The resulting 
kissing-loop interaction is required for efficient viral 
RNA synthesis in cell culture [118, 124]. The structural 
consequences of this contact are genotype-dependent 
and include a deep reorganization process in the 
folding of 3’SLII in genotype 2 viral transcripts, which 
could be related to the acquisition of a dimerizable 
conformation [33, 124]. Alternatively, genotype 1 
strains would be refractory to these rearrangements, 
pointing to an additional role of other closely related 
and highly conserved RNA structural domains in the 
HCV genome.  
ii) The bulge of the 5BSL3.2 domain may swap 
between two mutually exclusive contacts: one with the 
apical loop of the IIId subdomain of the IRES region 
[126, 127]; the other with the Alt region placed 
upstream of the CRE (Figure 2) [119, 126]. Both 
interactions are equally probable and show dissocia-
tion constants in the same range [125, 126]. 
Therefore, choosing between them may be 
determined by the presence of host and/or viral factors 
and have important conformational consequences. For 
example, chemical probing, SHAPE assays and 
antisense oligonucleotides microarrays revealed that 
the interaction IIId-5BSL3.2 induces a structural-tuning 
effect in the directly involved residues and even in the 
surrounding nucleotides [26, 33] in replication 
competent RNA transcripts representative of genotype 
1 strains (Rep construct; Figure 3). The 3D RNA 
structure prediction of the subdomain IIId for the Rep 
construct using these experimental constraints renders 
a model in which residues placed at the apical loop 
change their orientation to the solvent with respect to 
those included in a transcript containing the isolated 
IRES region (construct I; local root-mean square 
deviation RMSD of 6.84 Å; Figure 3). These 
reorganization events provide reliable insights into the 
potential implications for IRES function [26, 87]. In 
addition, the IIId-5BSL3.2 contact controls the 
structural switch at the 3’X-tail to promote the 
acquisition of the dimerizable form [33], likely by 
impeding the interaction 5BSL3.2-3’SLII. 
Importantly, as a result of the IIId-5BSL3.2 
interaction, both ends of the viral genome would be 
brought into close proximity, rendering a circular 
topology with important benefits for the virus: promote 
an increase in the local concentration of essential 
proteins and cofactors, endorse protection against 
cellular exonucleases and reduce the spatial distance 
between different functional domains to enhance the 
regulation mediated by RNA domains. 
All these structural and functional data provided 
above can be assembled into a biological model to 
explain the transitions between different steps of the 
HCV cycle [33] (Figure 4). During viral protein 
synthesis in the early infection stage, the subdomain 
IIId of the IRES would be mostly occluded by the 
translational machinery, thus favoring the contacts Alt-
5BSL3.2 and 3’SLII-5BSL3.2. Increasing levels of 
HCV proteins would favor the binding of NS5B and 
other factors to the 3’X-tail and the 5BSL3.2 domain, 
thus generating a molecular context in which the 
5BSL3.2-IIId and 5BSL3.2-Alt interactions would be 
equally feasible. Structural rearrangements and 
transitions from one to another may contribute to the 
establishment of an enhanced replication state [119] 
by repressing translation [87]. The increase in the viral 
RNA amount would displace the interaction equilibrium 
to promote the acquisition of the dimerizable 
conformer exposing the DLS motif in the presence of 
the core chaperone protein [115]. While dimerization is 
a common process in the genomes of the Retroviridae 
family, this is not known to account in the Flaviviridae 
family within infected cells. In fact, HCV virion is 
believed to contain a single copy of the genomic RNA. 
Therefore, HCV genome dimerization would play an 
unknown role during the infective cycle. It seems likely 
that future works using next generation high-
throughput technologies will help to elucidate this point 




Figure 3. RNA structural modeling of subdomain IIId. 
PDB RNA structure prediction of subdomain IIId using the 
MC-Fold/MC-Sym pipeline. Relative reactivity values 
obtained for different chemical reagents were used to 
generate the 3D models for subdomain IIId in the transcript I, 
which just contains the IRES region, and the replicative RNA 
Rep depicted on the top of the figure. Root mean-square 
deviation (RMSD) value was calculated from the comparison 
between both models in order to infer differences in the stem-
loop conformation. Color code: black, residues with a RMSD 
<3.5 Å with respect to molecule I; orange, nucleotides with a 
RMSD ranging from 3.5 to 6.0 Å with respect to I; red, 
residues with a RMSD >6.0 Å. 
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Figure 4. Proposed model for the role of long-range RNA-
RNA interactions in the HCV infective cycle. 1) In early 
infection, the naked genomic RNA initiates viral translation by 
directly recruiting the 40S ribosomal subunit at the 
subdomain IIId of the IRES region. This impedes the 
interaction IIId-5BSL3.2 and enhances the conformational 
rearrangement of the 3’ end mediated by the 5BSL3.2 
domain. 2) Viral protein accumulation unleashes the 
ribosome release from the IRES, while viral and cellular 
protein factors bind to the 3’SLII. This favors a translational-
repressed state by the establishment of the IIId-5BSL3.2 
contact and a favored replication process dependent on the 
interaction Alt-5BSL3.2. 3) The newly synthesized RNA 
molecules harbouring the preferred interaction IIId-5BSL3.2 
would expose the dimer linkage sequence (DLS) in an apical 
loop. In the presence of the core chaperone protein, 
dimerization is favored in these conformers. 4) Alternatively, 
HCV core protein can be recruited throughout the entire viral 
monomeric genome to constitute the nucleocapsid particle, 
which is then enveloped and released to the extracellular 
medium. Figure adapted from [25]. 
TARGETING HCV GENOMIC RNA WITH RNA 
LIGANDS  
Replication events in RNA viruses produce a wide 
spectrum of mutants due to the high error rates of the 
viral RNA-dependent RNA polymerases. This 
continuous variation phenomenon impedes the de-
velopment of efficient antiviral drugs that achieve 
sustained virological responses. In the case of HCV, 
the use of therapeutic cocktails containing generic 
compounds, such as α-interferon and modified 
nucleotides, provides viral sustained responses only 
for short periods of time [128]. Therefore, designing 
novel therapeutic strategies and antiviral drugs is a 
major goal in HCV investigations [129]. 
From a wide point of view, conserved structural 
and functional genomic domains are excellent candi-
dates for RNA-targeting due to their high genetic and 
structural robustness and conservation. Among the 
multiple antiviral strategies with nucleic acid-based 
inhibitors, the use of antisense oligonucleotides [16], 
small interfering RNAs (siRNAs) [130] and aptamers 
[131, 132] has rendered promising results [16]. The 
development of such therapeutics is challenging since 
nucleic acids must be efficiently targeted, stabilized 
and delivered to the infected cell. In this context, the 
great advances in chemical synthesis have 
successfully addressed some of these drawbacks by 
the incorporation of modified nucleotides with minimal 
interference in the desired inhibitory activity. Chemical 
modifications in the antiviral nucleic acid prevent 
degradation by exo- and endonucleases and improve 
its pharmacokinetic and pharmacodynamic properties, 
while reducing the immunogenicity [133]. Modifications 
include chemical substitutions at the ribose 2’ group, 
such as the inclusion of 2’-O-methyl, 2’-O-fluoro and 
2’-O-methoxyethyl groups.  
Antisense nucleic acids are oligonucleotides 
whose sequence is complementary to an existing 
nucleotide motif in a target RNA. After binding to their 
target sequence, they can impair key steps in the 
function of the RNA by competing with protein factors 
for the interaction site or by disrupting the structure of 
the target, thus impeding its activity. Different targets 
can be chosen: the promoter sequences, the 
translation initiation codon or the intron-exon junctions, 
among others. Antisense oligonucleotide inhibitors 
may also be used to interfere with maturation 
processes or, if DNA-based, to induce target 
degradation mediated by RNase H [16].  
The use of antisense oligonucleotides as anti-HCV 
agents directed against the RNA genome has been 
mainly focused on targeting the IRES domain. Of all 
the assayed inhibitors, ISIS 14803 was shown to be 
the most promising compound. It is a chemically 
modified DNA antisense oligonucleotide containing 
several thioate group substitutions [134, 135]. It binds 
to the translation initiation codon, placed in the apical 
loop of domain IV in the IRES region. Preclinical 
investigations in cell cultures and mouse models 
showed its ability to block HCV translation and 
replication [135]. These results encouraged further 
clinical trials of ISIS 14803, but with low success in 
phase I [136]. Interestingly, during the course of these 
investigations, the generation of quasispecies affecting 
the IRES region was analyzed. Although several 
variations were observed, none affected the 
complementary residues to ISIS 14803 or their 
neighboring sequences in domain IV, suggesting 
strong conservation constraints for this RNA domain 
[136].  
siRNAs are double-stranded, 21-nts long RNA 
molecules that trigger the cellular RNAi pathway. They 
operate by direct loading into the RISC (RNA-induced 
silencing complex), where the guide, antisense strand 
of the siRNA is specifically selected to target the 
complementary sequence motif in the viral RNA [130]. 
The degree of complementarity between the guide 
strand and the target sequence motif determines the 
silencing mechanism. Under perfect matching 
conditions, RISC mediates the degradation of the 
target RNA. In contrast, partial complementarity 
unleashes the translational repression. Thus, any 
mismatch will affect to the effectivity of the siRNA. 
Targeting highly conserved regions, such as the 5’ and 
the 3’ UTRs of RNA genomes, is an excellent 
candidate strategy to minimize the emergence of 
mutations in the target domain and to improve the 
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efficiency of the siRNA. Several investigations have 
demonstrated the viability of this approach, rendering 
efficient HCV inactivation mediated by synthetic 
siRNAs up to 80% in subgenomic replicon systems 
[137-142]. These promising results prompted the 
development of gene therapy strategies to induce 
long-term decrease of viral loads. Vector-based short 
hairpin RNAs (shRNAs) systems have emerged as an 
attractive strategy. In these constructs, the shRNA 
molecule is transcribed from a polymerase III promoter 
and then processed by Dicer in the cytoplasm to yield 
the mature, active siRNA molecule [143]. By using this 
approach, strong inhibition of HCV replication [138] 
and reliable decrease in viral titers for genotypes 1a 
and 2a ex vivo were observed even at concentrations 
as low as 2.5 nM [144-146]. The main drawbacks of 
this alternative are the appearance of escape mutants 
and the induction of the cellular interferon response 
pathway [147, 148]. Human cells transfected with 
siRNAs show a preferential activation of the Jak/Stat 
pathway and a general upregulation of the genes 
whose expression depends on the IFN cascade [148]. 
Other likely limitations include the overproduction of 
siRNAs, which may collapse the RNAi components 
used in the regulation of cell processes. 
Aptamers are short nucleic acids that efficiently 
and specifically recognize their target molecule via its 
3D architecture. Aptamers are isolated by SELEX 
(systematic evolution of ligands by exponential enrich-
ment) [149, 150]. This process consists of a number of 
iterative cycles applied to a randomized oligo-
nucleotide pool to finally yield an enriched population 
of molecules with the desired binding ability. Each 
SELEX cycle includes pool synthesis, binding, positive 
selection and amplification steps. Aptamers show 
great specificity, high affinity, easy large-scale 
production, pharmaceutical flexibility and low 
immunogenicity, thus constituting a feasible alternative 
for the development of novel therapeutic compounds. 
In 2004, the United States FDA approved the first 
aptamer drug, known as Pegaptanib (commercially 
available as Macugen, OSI Pharmaceuticals/Pfizer), 
for the treatment of age-related macular degeneration 
[151]. Other aptamer-based drugs that are currently 
being tested in clinical trials include antiangiogenic 
and anticoagulant targets [152].  
For HCV, conserved functional domains in the 
RNA genome have been proved to be effective 
aptamer targets. One of the preferred genomic 
functional elements to be targeted by aptamers in-
cludes the domain II and the subdomain IIId in the 
IRES region [153-157], the 3’X-tail [153] and the 
5BSL3.2 in the CRE [158]. Interfering with the folding 
and/or function of these regions inhibits translation 
and/or replication up to 90% levels at aptamer 
concentrations in the range of nanomolar. The efficacy 
of these molecules has been confirmed in vitro and in 
subgenomic replicon systems.  
The promising results returned by these 
investigations served as starting point for the 
development of chimeric molecules composed by 
different inhibitory modules with different specific 
targets and functional properties [157, 159-163]. It is 
tempting to propose that the use of such cocktails 
compounds would help to minimize the appearance of 
viral mutants, though to date no results have been 
provided. 
CONCLUSIONS 
In the past years, the use of conventional 
methodologies for the analysis of RNA folding actively 
contributed for the understanding of the structure-
function relationships in many RNA molecules. 
Currently, the advent of novel methodologies based on 
the next generation sequencing techniques for the 
analysis of RNA folding has complemented the 
previous picture and has moved toward a scenario in 
which the RNA is an active and essential cellular 
regulator partner. This new view has special relevance 
in RNA viruses, which use RNA folding to encode 
information required for adaptive viral fitness. Thus, 
complex and sophisticated control systems governed 
by RNA elements have evolved in many viral 
genomes, and likely in the cell transcriptome. These 
elements show high genetic robustness and are 
considered excellent targets for novel antiviral nucleic 
acids-based drugs. This can be a useful strategy to 
complement conventional antiviral therapies, such as 
the use of PEG-IFN. Improvements in DNA and RNA 
synthesis will likely help to develop innovative 
compounds that achieve sustained therapeutic re-
sponses with minimal toxicity and secondary effects.  
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